$21.840
+0.015 (+0.07%)At close
TECX News
TECX Events
Tectonic Therapeutic Reports Positive Phase 1a Results for TX2100
Tectonic Therapeutic announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational VHH-Fc fusion antagonist antibody targeting the APJ receptor, in healthy adult volunteers. The clinical trial was designed to support the advancement of clinical development for TX2100 as a potential treatment for Hereditary Hemorrhagic Telangiectasia, HHT, a rare, inherited vascular disorder with no currently approved therapies. The Company also announced that the U.S. Food and Drug Administration granted TX2100 Fast Track Designation for HHT. In addition, the FDA recently cleared the Company's Investigational New Drug, IND, application to conduct the upcoming TX2100 Phase 1b clinical trial in the U.S. in patients with HHT.
Tectonic Therapeutic Appoints Francois Nader as Independent Director
Tectonic Therapeutic announced it has appointed Francois Nader as an independent director to its board of directors, effective April 1, at which time he will also assume the role of chair of the board. Upon Nader assuming the role as independent director to the board of directors, Terry McGuire will resign from his role as chair of the board, a role which Nader will immediately assume. In order to provide for a smooth leadership transition, McGuire will remain a member of the board of directors until Tectonic's 2026 annual meeting of stockholders, which is anticipated to be in June.
Tectonic Therapeutics announces Q3 EPS of $1.02, below consensus estimate of $1.05
"Our team continued to advance our lead asset TX45 with the positive topline data from Part B of our Phase 1b study in patients with HFrEF. Following our recent presentation of the full Part A data set at the ESC Heart Failure 2025 Congress, the improvements demonstrated in both left heart function and pulmonary hemodynamics across both PH-HFrEF and PH-HFpEF populations suggest TX45 has the potential to be effective in a broad patient population," said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic. "Enrollment continues in our global APEX Phase 2 trial in PH-HFpEF, and we expect to report topline results from that study in 2026."
Truist: Tectonic pullback on Eli Lilly's relaxin data is excessive
Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following Eli Lilly's (LLY) data presentation and publication from their failed study in heart failure with preserved ejection fraction patients with recombinant long acting relaxin mimetic, volenrelaxin. The negative news "represents another hit to the emerging relaxin class of drugs," but the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's. The firm, which believes Tectonic's approach of targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls selloff "overdone," keeps a Buy rating and $64 price target on Tectonic shares.
Tectonic Therapeutic joins Russell 3000 Index
Tectonic Therapeutic announced that it has been added to the broad-market Russell 3000 Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.